Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
162.00    2.00 (1.25%)
Bid:
158.50
Ask:
162.00
Spread: 3.50 (2.208%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Holding(s) in Company

3 Oct 2019 08:26

RNS Number : 6406O
Hutchison China Meditech Limited
03 October 2019
Β 

TR-1: Standard form for notification of major holdings

Β 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Hutchison China MediTech Limited;

Legal Entity Identifier: 2138006X34YDQ6OBYE79

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Hutchison Healthcare Holdings Limited

City and country of registered office (if applicable)

British Virgin Islands

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

02/10/2019

6. Date on which issuer notified (DD/MM/YYYY):

03/10/2019

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

49.86%

-

49.86%

666,786,450

Position of previous notification (if

applicable)

51.15%

-

51.15%

Β 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

(KYG4672N1198)

332,478,770

-

49.86%

-

American Depositary Shares (US44842L1035)

-

-

-

-

SUBTOTAL 8. A

332,478,770

49.86%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

Β 

Β 

Β 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

CK Hutchison Holdings Limited - indirect, but ultimate, owner of the shareholder

49.86%

49.86%

Hutchison Whampoa (China) Limited - direct owner of the shareholder and a subsidiary of CK Hutchison Holdings Limited

49.86%

49.86%

Β 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Β 

Place of completion

Hong Kong

Date of completion

3 October 2019

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
HOLUOUBRKVARRRA
Date   Source Headline
30th Jun 20269:30 amRNSHUTCHMED to Announce 2026 Half-Year Results
29th Jun 20269:30 amRNSAnnouncement on blocklisting six monthly return
25th Jun 20267:00 amRNS-RHUTCHMED Highlights Phase II Data at ESMO
12th Jun 20267:00 amRNS-RHUTCHMED Highlights Sovleplenib Phase III Data
5th Jun 20269:30 amRNSBlock Admission Application
22nd May 20267:00 amRNS-RHUTCHMED Highlights Data to be Presented at ASCO
21st May 202611:00 amRNS-RNMPA approval for ELUNATE with TYVYT
12th May 202612:45 pmRNSAnnouncement on Results of Annual General Meeting
30th Apr 20269:30 amRNSTotal Voting Rights
29th Apr 202611:00 amRNS-RHUTCHMED Announces NDA Acceptance in China
9th Apr 20269:30 amRNS2025 Annual Report and Notice of AGM
9th Apr 20267:00 amRNS-RData to be Presented at AACR Annual Meeting 2026
23rd Mar 20267:00 amRNS-RHUTCHMED Initiates Phase III Trial of HMPL-760
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
9th Mar 20269:30 amRNSUpdate on Licensed Oncology Product in China
6th Mar 20268:30 amRNSDirectorate change
5th Mar 20261:00 pmRNS-RPublication of Form 20-F
5th Mar 202611:00 amRNS2025 Full Year Results and Business Updates
4th Mar 20268:30 amRNS-RHUTCHMED Initiates Global Trial of ATTC Candidate
6th Feb 20268:30 amRNSHUTCHMED to Announce 2025 Final Results
14th Jan 20267:00 amRNS-RPublication of Phase III Results in The Lancet
7th Jan 20267:00 amRNS-RPositive Topline Results of Phase III Trial
5th Jan 20267:00 amRNS-RSurufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
17th Dec 20257:00 amRNS-RHUTCHMED Initiates Development of ATTC Candidate
8th Dec 20257:00 amRNSExpanded NRDL Coverage + CIDL Inclusion in China
28th Nov 20258:30 amRNSTotal Voting Rights
27th Nov 20257:00 amRNS-RHUTCHMED Highlights Data at ESMO and ASH
5th Nov 20257:00 amRNS-REnrollment Complete in SAFFRON Global Phase III
3rd Nov 20257:00 amRNS-RUpdates from R&D Event
23rd Oct 20257:00 amRNS-RHUTCHMED Presents Data at AACR NCI EORTC
21st Oct 20259:30 amRNSVesting of awards under Long Term Incentive Plan
14th Oct 20259:30 amRNSAppointment of Independent Non-executive Director
13th Oct 20257:05 amRNS-RData to be Presented at the 2025 ESMO Congress
2nd Oct 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at ESMO
30th Sep 20259:30 amRNSTotal Voting Rights
12th Sep 20257:00 amRNS-RHUTCHMED to Present R&D Updates on October 31 2025
5th Sep 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at CSCO
26th Aug 20257:00 amRNSDirectorate Change
20th Aug 20257:00 amRNS-RHUTCHMED Completes Enrollment of Phase III Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.